Get started

Financials · ENTX

Entera Bio Ltd. (ENTX) financials

For the twelve months ended Sep 30, 2026, Entera Bio Ltd. reported $0 of revenue and -$29.43M of net income.

Revenue, TTM
$0
Revenue growth, YoY
-100.0%
Net income, TTM
-$29.43M
Free cash flow, TTM
-$15.84M
EPS, diluted, TTM
$0.38
Cash
$265.88M
Market cap
$546.1M
Annual revenue$42.0K
FY2018FY2025
Annual net income-$11.44M
FY2016FY2025
Annual free cash flow-$7.48M
FY2016FY2025

ENTX revenue and earnings growth

ENTX revenueQ3 2026$0

FY YoY
-76.8%
5Y CAGR
-35.1%

ENTX revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $42.0K, down 76.8% from fiscal 2024. Compound annual growth was -35.1% over 5 years.

ENTX net incomeQ3 2026-$15.60M

ENTX net income was -$15.60M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.20M a year earlier. For the full fiscal 2025 it was -$11.44M, compared with -$9.54M in fiscal 2024.

ENTX EPSQ3 2026$0.11

FY YoY
+0.0%

ENTX diluted EPS was $0.11 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was $0.25, up 0.0% from fiscal 2024.

ENTX free cash flowQ3 2026-$7.42M

ENTX free cash flow was -$7.42M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.54M a year earlier. For the full fiscal 2025 it was -$7.48M, compared with -$6.82M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$42.0K$181.0K$0$134.0K$571.0K$365.0K$236.0K$500.0K--
Cost of revenue$42.0K$172.0K$0$101.0K$373.0K$300.0K$210.0K---
Gross profit$0$9.0K$0$33.0K$198.0K$65.0K$26.0K---
Research and development$6.00M$4.50M$4.51M$5.85M$6.77M$6.38M$7.20M$8.52M$2.77M$2.65M
Selling, general and admin$398.0K$340.0K$4.43M$7.25M$5.69M$4.85M$4.28M$2.84M$8.57M$2.72M
Operating income-$11.53M-$9.59M-$8.89M-$13.02M-$12.22M-$11.17M-$11.45M-$10.86M-$11.34M-$5.37M
Pre-tax income-$11.44M-$9.53M-$8.86M-$12.93M-$12.25M-$11.20M-$10.79M-$10.30M--
Income tax$0$14.0K$29.0K$137.0K-$59.0K$20.0K----
Net income-$11.44M-$9.54M-$8.89M-$13.07M-$12.19M-$11.22M-$10.79M-$10.30M-$11.20M-$1.20M
EPS, basic$0.25$0.25$0.31$0.45$0.47$0.67$0.89$1.30$2.49$0.27
EPS, diluted$0.25$0.25$0.31$0.45$0.47$0.67$0.89$1.31$2.49$0.78
Diluted shares46.2M37.7M29.0M28.8M26.1M18.4M12.1M8.0M4.5M6.8M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$7.11M$8.74M$11.09M$12.38M$24.96M$8.66M$15.22M$7.51M$11.75M$4.16M
Receivables$0$126.0K$0$246.0K$183.0K$255.0K$278.0K$725.0K--
Current assets$15.30M$8.97M$11.26M$12.85M$25.33M$9.11M$15.64M$12.47M$12.42M-
Total assets$15.99M$9.39M$11.77M$13.13M$25.99M$9.72M$16.70M$13.34M$13.28M-
Current liabilities$2.20M$1.18M$1.09M$1.34M$3.16M$1.84M$4.59M$3.16M$2.02M-
Long-term debt--------$3.89M-
Total debt--------$3.89M-
Total liabilities$2.89M$1.31M$1.38M$1.37M$3.42M$2.21M$4.78M$3.23M$44.84M-
Shareholders' equity$13.10M$8.08M$10.39M$11.75M$22.57M$7.51M$13.77M$10.12M-$31.56M-$25.25M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$7.37M-$6.82M-$7.31M-$12.50M-$9.06M-$10.56M-$8.92M-$9.80M-$4.53M-$3.14M
Capital expenditures$107.0K$3.0K$17.0K$47.0K$17.0K$53.0K$40.0K$68.0K$51.0K$41.0K
Free cash flow-$7.48M-$6.82M-$7.33M-$12.55M-$9.08M-$10.61M-$8.96M-$9.86M-$4.58M-$3.18M
Investing cash flow-$107.0K-$3.0K-$17.0K-$102.0K-$17.0K-$53.0K$3.95M-$4.07M$1.00M-$1.12M
Financing cash flow$13.71M$4.48M$6.04M$13.0K$25.38M$4.05M$12.65M$9.62M$11.11M$7.22M
Stock-based compensation$2.75M$2.56M$1.69M$2.25M$1.86M$901.0K$1.48M$1.23M$4.88M$1.49M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-76.8%--100.0%-76.5%56.4%54.7%-52.8%---
EPS growth, YoY0.0%-19.4%-31.1%-4.3%------
Gross margin0.0%5.0%-24.6%34.7%17.8%11.0%---
Operating margin-27450.0%-5295.6%--9714.2%-2139.6%-3059.7%-4853.4%-2172.2%--
Net margin-27235.7%-5271.3%--9754.5%-2134.3%-3072.9%-4574.2%-2060.8%--
Free cash flow margin-17802.4%-3768.5%--9362.7%-1590.2%-2906.8%-3796.2%-1972.8%--
Return on equity-87.3%-118.1%-85.6%-111.2%-54.0%-149.3%-78.4%-101.9%--
Return on assets-71.5%-101.6%-75.6%-99.6%-46.9%-115.4%-64.6%-77.2%-84.3%-
Current ratio6.947.6310.329.588.014.953.413.946.15-

Source: XBRL data Entera Bio Ltd. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ENTX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ENTX$0-100.0%-$29.43M-$546.1M
AMGN$38.90B+8.2%$9.39B24.1%$249.05B
GILD$30.99B+6.5%-$3.86B-12.5%$207.00B
MRNA$2.52B+13.1%-$2.79B-110.5%$101.48B
ARGX$4.25B+88.6%$1.29B30.4%$57.55B
RVMD$0--$1.13B-$41.59B
BIIB$10.30B+2.3%$347.50M3.4%$36.71B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$16.98B

ENTX FAQ

8 questions
  • What is ENTX revenue?
    Entera Bio Ltd. (ENTX) reported $0 of revenue for the twelve months ended Sep 30, 2026. That is down 100.0% from the year before. Revenue for fiscal 2025 was $42.0K.
  • Is ENTX profitable?
    No. Entera Bio Ltd. reported a net loss of $29.43M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ENTX have?
    Entera Bio Ltd. reported $265.88M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ENTX revenue growing?
    Entera Bio Ltd.'s revenue changed -76.8% in fiscal 2025, to $42.0K. Its compound annual growth rate was -35.1% over 5 years.
  • What is ENTX free cash flow?
    Entera Bio Ltd. generated -$15.84M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$15.79M less capital expenditures.
  • What is ENTX earnings per share?
    Diluted earnings per share were $0.38 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ENTX last report financial results?
    The latest statements here come from Entera Bio Ltd.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.
  • Where does this ENTX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Entera Bio Ltd. files with the SEC. It is provided for information only and is not investment advice.